DHR — Danaher Corporation

Is DHR overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Diagnostics & Research

Neutral As of November 17, 2026

Danaher Corporation (DHR) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Diagnostics & Research) last closed at $225.77. The rating moved from Overbought to Neutral on November 13, 2026.

AI analysis

Danaher combines resilient, recurring revenue streams across life sciences and diagnostics with strong cash generation and a proven M&A playbook. Near-term upside is supported by sustained demand for bioprocessing tools, specialty distribution channels, and diagnostic consumables, while defensive sector positioning helps limit downside in choppy markets. Primary challenges include potential softness in capital spending, heightened competition in adjacent medtech areas, and execution risk on acquisitions. Social and filing signals are neutral, and the company’s balance sheet and diversified product base provide flexibility to navigate regulatory or macro headwinds.

Key factors

  • Diversified life sciences, diagnostics and biopharma services portfolio with recurring consumables and high-margin service revenue
  • Strong cash flow generation and history of disciplined, value-accretive M&A (supports growth and margin expansion)
  • Exposure to durable secular trends: bioprocessing demand, specialty pharmacy/distributor flows, and diagnostic testing
  • Defensive characteristics within healthcare that attract flows during risk-off periods while still capturing growth opportunities
  • Limited negative social/SEC signals (recent Form 4s neutral) and stable market positioning among large-cap healthcare names
  • Catalysts from continued adoption of bioprocessing tools, recurring service contracts, and potential tuck-in acquisitions

Risks

  • Slower global capital spending or weakness in end markets for lab equipment and hospital capital expenditure could compress near-term demand
  • Increased competition and margin pressure in adjacent medtech/surgical markets as robotics and consumable competition intensifies
  • Integration risk and execution missteps from acquisitions could dilute near-term profitability or raise restructuring costs
  • Regulatory or reimbursement changes (e.g., Medicare/Medicaid policy shifts) that indirectly affect customer economics or ordering patterns
  • Foreign exchange headwinds and macro slowdown in key geographies could reduce revenue converted to USD
  • Supply chain disruptions or component shortages that hinder fulfillment of instrument and consumable demand

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for DHR — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.